Human CD30/TNFRSF8 Protein (C-His)

Product Details


ApplicationELISA, BLI
FormatLiquid, Purified
Expression HostCHO
Target NameTNFRSF8, CD30, Ki-1
SpeciesHuman
SourcesRecombinant Human CD30 protein (phe19-Lys379) with C-terminus His tag is expressed in CHO cells.
accession numberP28908
Molecular WeightThe protein has a predicted molecular weight of 40 kDa. Under DTT-reducing conditions, it migrates at approximately 50-80 kDa on SDS-PAGE.
Affinity TagC-His
Purity>80% based on SDS-PAGE under reducing condition
Formulation1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin levelNot tested
Protein Concentration25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and HandlingBriefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

Background Information


CD30, also known as TNFRSF8, is a 120 kDa type I transmembrane glycoprotein from the TNF receptor superfamily. It is expressed on activated T, B, and NK cells, but not resting cells. CD30 is cleaved by metalloproteinases into a soluble form and is highly expressed in classical Hodgkin lymphoma and anaplastic large cell lymphoma. It interacts with proteins like TRAF1, TRAF2, and TRAF5, activating NF-kB signaling. This signaling regulates the proliferative potential of autoreactive CD8 T cells and protects against autoimmunity. CD30 is a therapeutic target in lymphoma immunotherapy and plays a role in autoimmune diseases like rheumatoid arthritis.